(ELOS) Announces Preliminary Fourth Quarter 2014 Revenue

Total revenue in the range of $72 to $74 million, up 20% to 24% y/y (pro-forma excluding Syneron Beauty), including approximately 50% product revenue growth in North America Strong UltraShape full commercial launch in U.S. with more than 50 systems sold Successful global launch of PicoWay with approximately $2.5 million in sales from mid-November through the end of the year

YOKNEAM, Israel, Jan. 8, 2015  — Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, today announced preliminary fourth quarter 2014 revenue results. The Company expects revenue for the fourth quarter 2014 to be in the range of $72 to $74 million, representing growth compared to the year-ago quarter of between 20% and 24% on a pro-forma basis (excluding Syneron Beauty). This includes strong growth in product revenue in North America of approximately 50%, in the EMEA region of approximately 15% and in the APAC region of approximately 30%.

In October, Syneron began the full commercial launch of the UltraShape system in the U.S., selling more than 50 systems in the fourth quarter. In mid-November, Syneron began the global launch of the PicoWay system, generating approximately $2.5 million in sales in the fourth quarter.

Amit Meridor, Chief Executive Officer of Syneron, said, “We delivered strong revenue growth in the fourth quarter 2014, gaining traction with the U.S. commercial launch of Ultrashape system and generating strong initial sales of our PicoWay product after the global launch during the quarter. The revenue growth also included solid performance in all geographies, with significant product revenue growth in North America, the EMEA region, and the APAC region. We ended the year with strong customer demand across our product portfolio and remain confident that we are well positioned for continued growth, particularly in North America, where we are beginning to see results from our sales and marketing investments and dedicated Body Shaping team.”

The financial estimates presented above are preliminary and remain subject to management’s final review as well as audit by the Company’s independent registered accounting firm. The Company intends to report complete fourth quarter and full year 2014 financial results in February. Details regarding the timing of the release of those results, as well as details of a conference call and publicly available webcast, will be announced in a subsequent press release.

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company’s technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.